Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Accounts Payables (2016 - 2025)

OptimizeRx's Accounts Payables history spans 16 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Accounts Payables fell 26.03% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, down 26.03%, while the annual FY2024 figure was $2.2 million, 3.19% down from the prior year.
  • Accounts Payables for Q3 2025 was $2.0 million at OptimizeRx, up from $2.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $3.4 million in Q1 2025 and bottomed at $499279.0 in Q1 2021.
  • The 5-year median for Accounts Payables is $1.3 million (2022), against an average of $1.5 million.
  • The largest annual shift saw Accounts Payables tumbled 36.9% in 2023 before it soared 298.46% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $606808.0 in 2021, then surged by 155.43% to $1.5 million in 2022, then surged by 43.68% to $2.2 million in 2023, then dropped by 3.19% to $2.2 million in 2024, then fell by 5.52% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Accounts Payables are $2.0 million (Q3 2025), $2.0 million (Q2 2025), and $3.4 million (Q1 2025).